Chronic Obstructive Pulmonary Disease (COPD) Treatment Market (By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiester Type 4 Inhibitor, Mucokinetics, Others; By Type: Chronic Bronchitis, Emphysema; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global chronic obstructive pulmonary disease (COPD) treatment market size was exhibited at USD 20.24 billion in 2022 and is projected to hit around USD 35.90 billion by 2032, growing at a CAGR of 5.9% during the forecast period 2023 to 2032.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, 2023 to 2032

Key Pointers:

  • North America generated more than 43.2% of the revenue share in 2022.
  • Europe held the second largest share of the global market in 2022.
  • The market in Asia Pacific is expected to grow at the fastest CAGR of 4.8% during the forecast period.
  • By Drug Class, the combination therapy segment captured the maximum market share in 2022.
  • By Type, the chronic bronchitis segment contributed to the largest market share in 2022.
  • By Distribution Channel, the retail pharmacies segment accounted for a remarkable market share in 2022.

Chronic obstructive pulmonary disease is a group of conditions affecting the lungs that lead to difficulty in breathing. Chronic bronchitis and emphysema are the two major types of chronic obstructive pulmonary diseases. Breathlessness is a key characteristic of COPD. In case of emphysema, the alveoli (tiny air sac) in the lungs is damaged. The walls of the alveoli are stretched, making the lungs bigger and resulting in difficulty in the movement of air. In chronic bronchitis, bronchial airways (breathing tubes) inside the lungs are inflamed. High prevalence of COPD across the globe and rich pipeline of drugs for COPD treatment are likely to drive the global market during the forecast period. Furthermore, increase in geriatric population and unhealthy lifestyle choices among various age groups are projected to propel the chronic obstructive pulmonary disease (COPD) treatment market in the near future.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 21.43 Billion

Market Size by 2032

USD 35.90 Billion

Growth Rate From 2023 to 2032

CAGR of 5.9%

Base Year

2022

Forecast Period

2023 to 2032

Segments Covered

By Drug Class, By Type, and By Distribution Channel

Market Analysis (Terms Used)

Value (US$ Million/Billion) or (Volume/Units)

Regional Scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key Companies Profiled

GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceuticals, Pfizer, Mylan, Chiesi, Roche, Merck & Co. and Others.

 

Rise in Prevalence of COPD Across Globe

Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active smoking or passive smoking). According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2019. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD is projected to increase in the near future due to continued exposure to COPD risk factors, rise in incidence of interstitial lung diseases, and aging population across the world. This is anticipated to augment the chronic obstructive pulmonary disease treatment market in the near future.

Increase in Adoption of More Effective Combination Therapy to Drive Global COPD Treatment Market

Combination therapies include LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs. Adoption of combination therapy is increasing, as it is more effective than separate use of bronchodilators and corticosteroids. Increase in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is expected to fuel the global chronic obstructive pulmonary disease treatment market. Combination therapy is more effective than monotherapy for improving symptoms and quality of life.

Growth in Success Rate of COPD Treatment to Augment Combination Therapy Segment

In terms of drug class, the global COPD treatment market has been classified into combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitor, mucokinetics, and others. The combination therapy segment held major share of around 51.9% of the global market in 2022. It is likely to dominate the global market during the forecast period, owing to the increase in efficacy of combination therapy in COPD treatment. Rise in the success rate of combination therapy in COPD treatment and recent regulatory approvals have augmented the adoption of combination therapy. This is projected to drive the segment during the forecast period.

Surge in Airflow Blockage and Breathing Issues among Smokers Fueling Chronic Bronchitis Segment

In terms of type, the global COPD treatment market has been bifurcated into chronic bronchitis and emphysema. The chronic bronchitis segment accounted for the largest chronic obstructive pulmonary disease treatment market share in 2022. Chronic bronchitis is a group of lung diseases that causes airflow blockage and breathing issues. It is widespread among smokers and rising at a rapid pace.

Rise in Number of COPD Therapeutics Dispensed to Boost Retail Pharmacies Segment

Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is anticipated to account for major share of the global chronic obstructive pulmonary disease treatment market during the forecast period. The segment is expected to grow at a rapid pace during the forecast period, owing to the increase in number of COPD therapeutics dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries.

Regional Outlook of Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

As per chronic obstructive pulmonary disease treatment market analysis, North America accounted for the largest share of around 43.2% of the global market in 2022. The market in the region is projected to grow at a CAGR of 4.4% from 2023 to 2032. This can be ascribed to the highly structured health care industry and availability of well-defined reimbursement policies from private and public health insurance firms. Furthermore, rise in research & development activities to provide advanced and efficient products, and presence of a large number of players are driving the chronic obstructive pulmonary disease treatment market size in North America.

Europe held the second largest share of the global market in 2022. Well-developed health care infrastructure and increase in incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region.

The market in Asia Pacific is expected to grow at the fastest CAGR of 4.8% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.

Key Developments in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

  • In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments would be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
  • In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 271 Mn. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
  • In October 2021, Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca's Symbicort. It is anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).
  • In January 2019, CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.

Some of the prominent players in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market include:

  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Teva Pharmaceuticals
  • Pfizer
  • Mylan
  • Chiesi
  • Roche
  • Merck & Co.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market.

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiester Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 

5.1. COVID-19 Landscape: Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class

8.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class, 2023-2032

8.1.1 Combination Therapy

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Bronchodilators

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Corticosteroids

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Phosphodiester Type 4 Inhibitor

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Mucokinetics

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Type

9.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Type, 2023-2032

9.1.1. Chronic Bronchitis

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Emphysema

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel 

10.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.2. Market Revenue and Forecast, by Type (2020-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 12. Company Profiles

12.1. GlaxoSmithKline (GSK)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. AstraZeneca

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Boehringer Ingelheim

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Teva Pharmaceuticals

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Pfizer

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Mylan

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Chiesi

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Roche

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Merck & Co.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers